FDA approves a four-pack Zepbound vial presentation

The Food and Drug Administration approved a labeling supplement on February 7, 2025, allowing Eli Lilly to sell Zepbound (tirzepatide) in a four-pack vial carton, packaging a month's worth of single-dose vials together ^[1]. The approval covers NDA 217806, supplement S-020, a "Prior Approval Supplement" that Lilly submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act ^[1].

According to the FDA approval letter, Lilly filed the supplement on October 15, 2024, and the agency completed its review before signing off effective the date of the letter ^[1]. The letter states the change is limited to labeling that adds "Zepbound single-dose vials in a four-pack vial presentation" ^[1]. The letter does not describe dosage strengths included in the four-pack, pricing, or when the product will reach pharmacies, so those details are not yet known from this source.

The approval letter, signed by Ramesh Raghavachari of the FDA's Division of Product Quality Assessment IV, also lays out routine post-approval steps Lilly must follow. The company has 14 days to submit the final content of labeling in structured product labeling format and to update any other pending supplements that reference this NDA ^[1]. Lilly also has up to 30 days after printing to submit final printed carton and container labels to the FDA, though the letter notes that FDA approval of those labels is not required before they can be used ^[1].

Why it matters for patients

A four-pack vial carton changes how a month of Zepbound doses can be bundled and dispensed, which may affect how pharmacies stock and fill prescriptions. The approval letter is a manufacturing and labeling document, not a change to the drug's approved uses, dosing schedule, or safety information ^[1]. Nothing in the letter addresses cost to patients, insurance coverage, or how quickly this vial configuration will become available at pharmacies.

The letter also does not compare this vial presentation to Zepbound's other existing packaging, such as single-dose pens, so patients who already use Zepbound may not yet know whether or how this option will change what they see at the pharmacy counter. Because the source is limited to the regulatory approval letter itself, questions about real-world availability, shelf life, or storage differences between this four-pack and other Zepbound presentations are not addressed and remain unknown from this document.

What happens next

Under the terms of the approval, Lilly was required to submit the finalized prescribing information in structured product labeling format within 14 days of the February 7, 2025 letter, meaning by around February 21, 2025 ^[1]. The company must also submit final printed carton and container labels within 30 days of when those labels are printed, though the letter does not specify a printing date ^[1]. The letter states that FDA approval of those printed labels is not required before Lilly can begin using them, so the four-pack packaging could reach the market before any further agency sign-off ^[1]. No information in the source indicates when the four-pack carton will actually appear in pharmacies or how it will be marketed to patients and prescribers.